365NEWS gathered that Pharmacy Plus, a prominent pharmaceutical company, has launched Duostam, an innovative medication for the treatment of Benign Prostatic Hyperplasia (BPH), commonly referred to as prostate enlargement.
The condition, characterized by an increase in prostate gland size due to cellular overgrowth, is a leading cause of Lower Urinary Tract Symptoms (LUTS) in aging men.
The announcement was made during the 97th Pharmaceutical Society of Nigeria (PSN) Conference held in Uyo.
Speaking at the event, Professor Ikenna Nnabugwu, a leading expert, noted the growing prevalence of LUTS/BPH, which affects approximately 20% of men aged 40 and above.
He highlighted the debilitating impact of BPH on quality of life, emphasizing the need for advanced treatment solutions.
In response, Pharmacy Plus introduced Duostam as a game-changer in BPH management.
The new drug offers a range of benefits, including relief from Lower Urinary Tract Symptoms (LUTS), enhanced patient-reported quality of life (QoL), slowed progression of the disease, a reduced risk of acute urinary retention (AUR), and a minimized risk of bleeding associated with an enlarged prostate.
The Managing Director of Pharmacy Plus, Chukwuemeka Obi, affirmed the company’s commitment to advancing healthcare through innovative research.
“As a research-driven pharmaceutical company, we are dedicated to developing effective treatment options for patients. Clinical studies have validated the efficacy and safety of the Duostam when used as prescribed,” Obi said.
The launch of Duostam signifies a major milestone in addressing the challenges faced by men living with BPH, promising a safer and more effective approach to managing the condition.
Pharmacy Plus Pharmacy Plus is a leading pharmaceutical company renowned for its commitment to innovation and excellence in healthcare solutions.
Driven by cutting-edge research, the company delivers high-quality medications to meet the diverse needs of patients globally.
